Literature DB >> 9916127

Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal.

L E Benjamin1, D Golijanin, A Itin, D Pode, E Keshet.   

Abstract

Features that distinguish tumor vasculatures from normal blood vessels are sought to enable the destruction of preformed tumor vessels. We show that blood vessels in both a xenografted tumor and primary human tumors contain a sizable fraction of immature blood vessels that have not yet recruited periendothelial cells. These immature vessels are selectively obliterated as a consequence of vascular endothelial growth factor (VEGF) withdrawal. In a xenografted glioma, the selective vulnerability of immature vessels to VEGF loss was demonstrated by downregulating VEGF transgene expression using a tetracycline-regulated expression system. In human prostate cancer, the constitutive production of VEGF by the glandular epithelium was suppressed as a consequence of androgen-ablation therapy. VEGF loss led, in turn, to selective apoptosis of endothelial cells in vessels devoid of periendothelial cells. These results suggest that the unique dependence on VEGF of blood vessels lacking periendothelial cells can be exploited to reduce an existing tumor vasculature.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9916127      PMCID: PMC407882          DOI: 10.1172/JCI5028

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation.

Authors:  T N Sato; Y Tozawa; U Deutsch; K Wolburg-Buchholz; Y Fujiwara; M Gendron-Maguire; T Gridley; H Wolburg; W Risau; Y Qin
Journal:  Nature       Date:  1995-07-06       Impact factor: 49.962

2.  Cellular response to androgen depletion and repletion in the rat ventral prostate: autoradiography and morphometric analysis.

Authors:  H F English; J R Drago; R J Santen
Journal:  Prostate       Date:  1985       Impact factor: 4.104

Review 3.  Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy.

Authors:  J Denekamp
Journal:  Br J Radiol       Date:  1993-03       Impact factor: 3.039

4.  Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases.

Authors:  J Pe'er; D Shweiki; A Itin; I Hemo; H Gnessin; E Keshet
Journal:  Lab Invest       Date:  1995-06       Impact factor: 5.662

5.  Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression.

Authors:  L Holmgren; M S O'Reilly; J Folkman
Journal:  Nat Med       Date:  1995-02       Impact factor: 53.440

6.  Requirement of vascular integrin alpha v beta 3 for angiogenesis.

Authors:  P C Brooks; R A Clark; D A Cheresh
Journal:  Science       Date:  1994-04-22       Impact factor: 47.728

7.  Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis.

Authors:  R S Warren; H Yuan; M R Matli; N A Gillett; N Ferrara
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

8.  Definition of two angiogenic pathways by distinct alpha v integrins.

Authors:  M Friedlander; P C Brooks; R W Shaffer; C M Kincaid; J A Varner; D A Cheresh
Journal:  Science       Date:  1995-12-01       Impact factor: 47.728

9.  Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.

Authors:  M S O'Reilly; L Holmgren; Y Shing; C Chen; R A Rosenthal; M Moses; W S Lane; Y Cao; E H Sage; J Folkman
Journal:  Cell       Date:  1994-10-21       Impact factor: 41.582

10.  Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity.

Authors:  T Alon; I Hemo; A Itin; J Pe'er; J Stone; E Keshet
Journal:  Nat Med       Date:  1995-10       Impact factor: 53.440

View more
  294 in total

Review 1.  Anticancer drug targets: approaching angiogenesis.

Authors:  E Keshet; S A Ben-Sasson
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

2.  Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.

Authors:  D Hanahan; G Bergers; E Bergsland
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

Review 3.  Physiology of angiogenesis.

Authors:  H Kurz
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

4.  Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery.

Authors:  C Sundberg; J A Nagy; L F Brown; D Feng; I A Eckelhoefer; E J Manseau; A M Dvorak; H F Dvorak
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

5.  Anti-angiogenic therapy for uveal melanoma--more haste, less speed.

Authors:  A W Stitt; T A Gardiner
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

6.  Angiogenesis in chronically ischaemic human heart following percutaneous myocardial revascularisation.

Authors:  J M Cotton; M R Thomas; B J Dunmore; J Salisbury; A M Shah; N P J Brindle
Journal:  Heart       Date:  2002-03       Impact factor: 5.994

7.  Bartonella-associated endothelial proliferation depends on inhibition of apoptosis.

Authors:  James E Kirby; Dawn M Nekorchuk
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

8.  Angiogenic revascularisation in ischaemic disease. Molecular techniques hold promise, though they are still some way off.

Authors:  N P Brindle; M J McCarthy; P R Bell
Journal:  BMJ       Date:  1999-06-05

9.  Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation.

Authors:  C Cursiefen; C Hofmann-Rummelt; M Küchle; U Schlötzer-Schrehardt
Journal:  Br J Ophthalmol       Date:  2003-01       Impact factor: 4.638

Review 10.  Applications of magnetic resonance in model systems: tumor biology and physiology.

Authors:  R J Gillies; Z M Bhujwalla; J Evelhoch; M Garwood; M Neeman; S P Robinson; C H Sotak; B Van Der Sanden
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.